Bio-Path awarded $244.

Government’s Qualifying Therapeutic Discover Task Program, established beneath the Patient Safety and Affordable Care Take action. THE INNER Revenue Service in discussion with the U.S. Department of Health insurance and Human Solutions qualified investments due to the program. Bio-Path expects to get the money from the grant by the finish of the entire year 2010. Peter Nielsen, President and CEO of Bio-Path, commented, We have become very happy to receive grant financing to aid the on-heading Liposomal Grb-2 scientific trial.The new study’s authors, led by Dr. Olof Stephansson, a researcher at Karolinska Institutet in Stockholm, Sweden, estimate depression during pregnancy affects between 7 and 19 % of expecting moms in ecumenically created countries. Some earlier studies have suggested a minimal risk of limb deformities or rare lung and heart problems in newborns from taking specific classes of antidepressants, notes The Mayo Clinic. Additional studies have found depression can be harmful to a new baby, so the great things about taking antidepressants outweigh any low risks.